The Role of Irisin throughout Women's Life Span.

HPG axis bone health functional hypothalamic amenorrhea (FHA) gestational diabetes (GDM) irisin menopause metabolism polycystic ovary syndrome (PCOS) reproduction

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
09 Dec 2023
Historique:
received: 12 11 2023
revised: 25 11 2023
accepted: 07 12 2023
medline: 23 12 2023
pubmed: 23 12 2023
entrez: 23 12 2023
Statut: epublish

Résumé

Since its discovery, much attention has been drawn to irisin's potential role in metabolic and reproductive diseases. This narrative review summarizes and updates the possible role played by this fascinating molecule in different physiological (puberty and menopause) and pathological (polycystic ovary syndrome (PCOS), functional hypothalamic amenorrhea (FHA), endometriosis, and gestational diabetes) conditions that can affect women throughout their entire lives. Irisin appears to be an important factor for the hypothalamic-pituitary-gonadal axis activation, and appears to play a role in the timing of puberty onset. Serum irisin levels have been proposed as a biomarker for predicting the future development of gestational diabetes (GDM). Its role in PCOS is still controversial, although an "irisin resistance" mechanism has been hypothesized. In addition to its impact on metabolism, irisin also appears to influence bone health. Irisin levels are inversely correlated with the prevalence of fractures in postmenopausal women. Similar mechanisms have also been postulated in young women with FHA. In clinical settings, further controlled, prospective and randomized clinical trials are needed to investigate the casual relationship between irisin levels and the conditions described and, in turn, to establish the role of irisin as a prognostic/diagnostic biomarker or a therapeutic target.

Identifiants

pubmed: 38137481
pii: biomedicines11123260
doi: 10.3390/biomedicines11123260
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Auteurs

Federica Barbagallo (F)

Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy.

Rossella Cannarella (R)

Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy.
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44125, USA.

Vincenzo Garofalo (V)

Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy.

Marta Marino (M)

Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy.

Sandro La Vignera (S)

Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy.

Rosita A Condorelli (RA)

Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy.

Lara Tiranini (L)

Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, 27100 Pavia, Italy.

Rossella E Nappi (RE)

Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, 27100 Pavia, Italy.
Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS San Matteo Foundation, 27100 Pavia, Italy.

Aldo E Calogero (AE)

Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy.

Classifications MeSH